Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: A flexible-dose, open-label pilot trial

Journal of Anxiety Disorders

Volumn 22, Issue 8, 2008, Pages 1480-1486

  Katzman, M A ^a,b,c,d   Vermani, M ^a   Jacobs, L ^a   Marcus, M ^a   Kong, B ^a   Lessard, S ^e   Galarraga, W ^f   Struzik, L ^a   Gendron, A ^g  

^a START Clinic for Mood and Anxiety Disorders   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^d LAKEHEAD UNIVERSITY   (Canada)

^e Hopital Montfort Hospital   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g ASTRAZENECA   (United Kingdom)

Author keywords

Anxiety; Atypical antipsychotics; Augmentation; Disorder; Efficacy; Remission; Safety; Treatment; Trial

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; QUETIAPINE; SERTRALINE; VENLAFAXINE;

ADULT; AGED; AGITATION; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEAD AND NECK PAIN; HUMAN; IRRITABILITY; LABORATORY TEST; MALE; MENTAL CONCENTRATION; NAUSEA; NIGHTMARE; OUTPATIENT; PAIN; PANIC; PENN STATE WORRY QUESTIONNAIRE; PITTSBURGH SLEEP QUALITY INDEX; PRESYNCOPE; QUESTIONNAIRE; REMISSION; RESTLESS LEGS SYNDROME; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEATING; TRADITIONAL MEDICINE; TREATMENT DURATION; VITAL SIGN; WEIGHT CHANGE; WEIGHT GAIN; XEROSTOMIA;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PILOT PROJECTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; RISPERIDONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 53149142767     PISSN: 08876185     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.janxdis.2008.03.002     Document Type: Article

References (39)

1. Andrews G., Sanderson K., Slade T., and Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bulletin of the World Health Organization 78 (2000) 446-454
2. Baldwin D.S., and Nair R.V. Escitalopram in the treatment of generalized anxiety disorder. Expert Review of Neurotherapeutics 5 (2005) 443-449
3. Ballenger J.C., Davidson J.R.T., Lecrubier Y., Nutt D.J., Borkovec T.D., Rickels K., et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. Journal of Clinical Psychiatry 62 Suppl. 11 (2001) 53-58
4. Blazer D.G., Hughes D., George L.K., Swartz M., and Boyar J. Generalized anxiety disorder. In: Robins L.N., and Racier D.A. (Eds). Psychiatric disorders in America: the epidemiologic catchment area study (1991), The Free Press, New York 180-203
5. Bogan A.M., Koran L.M., Chuong H.W., Vapnik T., and Bystritsky A. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. Journal of Clinical Psychiatry 66 (2005) 73-79
6. Brawman-Mintzer O., Knapp R.G., and Nietert P.J. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 66 (2005) 1321-1325
7. Brawman-Mintzer O., Nietert P.J., Rynn M.A., and Rickels K. Quetiapine monotherapy in patients with generalised anxiety disorder. Poster session presented at the 26th annual conference of the anxiety disorders association of America. Miami, FL, USA, March (2006)
8. Buckley P.F. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Current Medical Research and Opinion 20 (2004) 1357-1363
9. Bystritsky A., Ackerman D.L., Rosen R.M., Vapnik T., Gorbis E., Maidment K.M., et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Journal of Clinical Psychiatry 65 (2004) 565-568
10. Calabrese J.R., Keck Jr. P.E., Macfadden W., Minkwitz M., Ketter T.A., Weisler R.H., et al., The BOLDER Study Group. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 162 (2005) 1351-1360
11. Citrome L., and Volavka J. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Postgraduate Medicine 116 4 (2004) 49-63
12. Denys D., de Geus F., Van Megen H.J., and Westenberg H.G. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. Journal of Clinical Psychiatry 65 (2004) 1040-1048
13. Devarajan S., Ali J., and Dursun S.M. Quetiapine plus SSRI in treatment-resistant depression: possible mechanisms. Psychopharmacology 185 (2006) 402-403
14. Doree, J. P., Tourjman, S. V., Kunicki, S., Desrosiers, J., Vanier, C., Elie, R., et al. (2004). Comparison of quetiapine versus lithium treatment of resistant depression [Abstract]. American Psychiatric Association. Retrieved from http://www.psych.org/edu/other_res/lib_archives/archives/meetings/2004nra.htm.
15. Galynker I., Khan A., Grebchenko Y., Ten A., Malaya L., Yanowitch P., et al. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. Journal of Clinical Psychiatry 66 (2005) 544
16. Gelenberg A.J., Lydiard R.B., Rudolph R.L., Aguiar L., Haskins J.T., and Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. Journal of the American Medical Association 283 (2000) 3082-3088
17. Hamner M.B., Deitsch S.E., Brodrick P.S., Ulmer H.G., and Lorberbaum J.P. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. Journal of Clinical Psychopharmacology 23 (2003) 15-20
18. Hirschfeld R.M., Weisler R.H., Raines S.R., and Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 67 (2006) 355-362
19. Horácek J. Novel antipsychotics and extrapyramidal side effects. Theory and reality. Pharmacopsychiatry 33 Suppl. (2000) 34-42
20. Kennedy S.H., Lam R.W., Cohen N.L., and Ravindran A.V. Clinical guidelines for the treatment of depressive disorders. Part IV. Medications and other biological treatments. Canadian Journal of Psychiatry 46 Suppl. 1 (2001) 38S-58S
21. Li X., May R.S., Tolbert L.C., Jackson W.T., Flournoy J.M., and Baxter L.R. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. Journal of Clinical Psychiatry 66 (2005) 736-743
22. Macfadden, W., Calabrese, J. R., McCoy, R., Minkwitz, M., Wilson, E., & Mullen, J. (2004). Antianxiety effects analysis of quetiapine in bipolar depression [Abstract]. American Psychiatric Association. Retrieved from http://www.psych.org/edu/other_res/lib_archives/archives/meetings/2004nra.htm.
23. McIntyre A., Gendron A., and McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors (SSRIs) or venlafaxine in patients with major depression, comorbid anxiety and residual depressive symptoms: a randomized, placebo controlled pilot study. Depression and Anxiety 24 7 (2007) 487-494
24. Michelini S., Cassano G.B., Frare F., and Perugi G. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry 29 (1996) 127-134
25. Montgomery S.A. Pregabalin for the treatment of generalised anxiety disorder. Expert Opinion on Pharmacotherapy 7 (2006) 2139-2154
26. Mullen J., Jibson M.D., Sweitzer D., and The QUEST Study Group. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clinical Therapeutics 23 (2001) 1839-1854
27. Pollack M.H., Simon N.M., Zalta A.K., Worthington J.J., Hoge E.A., Mick E., et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biological Psychiatry 59 (2005) 211-215
28. Pollack M.H., Zaninelli R., Goddard A., McCafferty J.P., Bellew K.M., Burnham D.B., et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62 (2001) 350-357
29. Rickels K., Downing R., Schweizer E., and Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Archives of General Psychiatry 50 (1993) 884-895
30. Schutters S.I., Van Megen H.J., and Westenberg H.G. Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. Journal of Clinical Psychiatry 66 (2005) 540-542
31. Sharpley A.L., Attenburrow M.E., Hafizi S., and Cowen P.J. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. Journal of Clinical Psychiatry 66 (2005) 450-454
32. Sharpley A.L., Vassallo C.M., and Cowen P.J. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo. Biological Psychiatry 47 (2000) 468-470
33. Shayegan D.K., and Stahl S.M. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectrums 9 Suppl. 11 (2004) 6-14
34. Thase M.E. Efficacy of quetiapine monotherapy in bipolar I and II depression: a confirmatory double-blind, placebo-controlled study. Journal of Clinical Pharmacology 26 (2006) 600-609
35. Weiss E.L., Potenza M.N., McDougle C.J., and Epperson C.N. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. Journal of Clinical Psychiatry 60 (1999) 524-527
36. Wittchen H.U., Zhao S., Kessler R.C., and Eaton W.W. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Archives of General Psychiatry 51 (1994) 355-364
37. Worthington III J.J., Kinrys G., Wygant L.E., and Pollack M.H. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. International Clinical Psychopharmacology 20 (2005) 9-11
38. Yargic L.I., Corapcioglu A., Kocabasoglu N., Erdogan A., Koroglu G., and Yilmaz D. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. International Journal of Psychiatry in Clinical Practice 8 (2004) 205-211
39. Yatham L.N., Goldstein J.M., Vieta E., Bowden C.L., Grunze H., Post R.M., et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. Journal of Clinical Psychiatry 66 Suppl. 5 (2005) 40-48